Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Total Liabilities for 9 consecutive years, with -$32.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 112.08% to -$32.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$32.6 million, a 112.08% decrease, with the full-year FY2025 number at -$32.6 million, down 112.08% from a year prior.
  • Total Liabilities was -$32.6 million for Q4 2025 at Akebia Therapeutics, up from -$41.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $519.2 million in Q1 2022 to a low of -$41.6 million in Q3 2025.
  • A 5-year average of $267.4 million and a median of $277.5 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 29.86% in 2021, then crashed 186.58% in 2025.
  • Akebia Therapeutics' Total Liabilities stood at $455.3 million in 2021, then decreased by 22.95% to $350.8 million in 2022, then fell by 22.39% to $272.3 million in 2023, then decreased by 0.89% to $269.9 million in 2024, then crashed by 112.08% to -$32.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Total Liabilities are -$32.6 million (Q4 2025), -$41.6 million (Q3 2025), and -$29.2 million (Q2 2025).